- Case report
- Open Access
- Open Peer Review
Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report
© Rogan and Thomas; licensee BioMed Central Ltd. 2007
- Received: 15 June 2007
- Accepted: 05 September 2007
- Published: 05 September 2007
A 78-year-old white male from Iowa in the United States of America receiving the anti- tumor necrois factor (TNF) agent infliximab therapy for rheumatoid arthritis developed a cheek ulcer which failed to respond to empiric antibiotic therapy. He subsequently presented with progressive respiratory failure from miliary coccidioidomycosis which proved fatal. The patient vacationed in Arizona 6 months previously and likely contracted the organism there as Iowa is not an endemic area for coccidioidomycosis. Respiratory failure from miliary infiltration is an uncommon presentation of coccidioidomycosis. Physicians should be aware of the importance of travel history and potential for life-threatening coccidioidomycosis in patients receiving tumor necrosis factor inhibitors.
- Travel History
- Progressive Respiratory Failure
- Purify Protein Derivative Skin
Tumour necrosis factor-α (TNF-α) is a cytokine that plays an important role in inflammation. In pathophysiological conditions, generation of TNF at high levels leads to the development of inflammatory responses that are hallmarks of many diseases. Anti- tumor necrosis factor agents are being increasingly used for immunomodulation in a wide variety of clinical conditions including inflammatory bowel disease, arthritides, psoriasis and atopic dermatitis. Early data suggests that they may have potential roles in vasculitides  and possibly sarcoidosis . It is estimated that there are over 400,000 people currently on anti- TNF-α therapies worldwide . These agents include: infliximab which is a chimeric mouse/human monoclonal IgG1 antibody directed at TNF; etanercept: which consists of 2 two copies of recombinant human TNF receptor p75 attached to the Fc portion of IgG1 and adalimumab-a fully human monoclonal antibody. Newer anti- TNF-α agents such as CDP571, CDP870 and onercept are currently being investigated in clinical trials . Despite increasing popularity and broadening indications for usage, the anti-TNF agents have been associated with a wide variety of infections. We report a case of fatal miliary coccidioidomycosis in a patient receiving infliximab therapy.
Coccidioidomycosis is a fungal disease caused by 2 nearly identical species, Coccidioides immitis and C. posadasii. It is endemic to areas of southwestern USA known as the Lower Sonora Life Zone. This semiarid zone encompasses southern Texas, Arizona, New Mexico, and much of central and southern California. Human infection occurs as a result of inhalation of arthroconidia. The majority of people exposed are asymptomatic but some develop an influenza-like illness and occasionally pneumonia. Dissemination is uncommon in immunocompetent hosts [5, 6].
Coccidioidomycosis is associated with skin lesions such as the cheek lesion that our patient developed approximately 5-weeks prior to transfer to our ICU. We speculate that he contracted coccidioidomycosis in Arizona and that dissemination occurred over time whilst been treated with infliximab. Cutaneous involvement occurs by haematogenous dissemination to the skin or, much more rarely, from a primary cutaneous infection . This lesion was mistakenly thought to represent a localized area of cellulitis and the patient was empirically treated with antibiotics for several weeks. Early biopsy and culture of this lesion may have led to a prompt diagnosis of coccidioidomycosis and perhaps the fatal outcome could have been prevented. This case highlights the consequences of a delay in diagnosis in patients receiving anti-TNF therapies.
Disseminated coccidioidomycosis has been previously described in immunosuppressed patients. For example, it is well recognized in the solid organ transplant population where it is thought to be a result of a primary infection or reactivation of latent infection . Other groups of patients at risk for dissemination include pregnant women, African Americans and Filipinos, diabetics, HIV-positive patients and patients with lymphoma and other forms of immunosupression .
A recent meta-analysis of the anti-TNF antibody agents infiximab and adalumimab in 3493 patients with rheumatoid arthritis demonstrated increased risk of serious infections in 126 patients but only 1 case of coccidioidomycosis . A multi-center study of rheumatologic patients from coccidioidomycosis endemic regions also demonstrated increased risk of coccidioidomycosis in patients treated with TNF antagonists . In this study, 13 cases of coccidioidomycosis (12 associated with infliximab and 1 with etanercept) were identified among 918 patients being treated with TNF antagonist over a 5-year period. Interestingly, all patients presented with lobar pneumonia. None of the patients in this study had the bilateral, miliary infiltrates and progressive respiratory failure that we describe in this case. Only 5 patients were hospitalized: 2 died – one from meningeal coccidioidomycosis and one from central venous catheter related-sepsis.
In summary, anti TNF-α therapy is becoming more widespread in clinical use. These agents may predispose to disseminated, deep fungal infection and tuberculosis. Current recommendations prior to anti-TNF-α therapy include a chest x-ray, a tuberculin skin test and coccidioidomycosis serology. However serology may be an unreliable indicator of disease in such patients [5, 10]. Coccidioidomycosis is one of the great imitators and may be the etiology of serous cavity infections such as pericarditis, empyema and peritonitis. It should be considered in the differential among patients presenting with atypical infections and a history of exposure to an endemic area. A careful travel history should be obtained in all patients prior to commencing anti TNF therapy. Physicians should maintain a high level of vigilance and promptly investigate any new signs or symptoms such as skin lesions in these patients. Antifungal prophylaxis with azole therapy is currently recommended for some high risk patients undergoing organ transplant from endemic areas . Azole prophylaxis may have a role in patients on anti TNF-α therapy that live in endemic areas. In our case, the patient visited an endemic area for a brief period and then developed fatal coccidioidomycosis 6-months later. Further studies regarding the incidence of coccidioidomycosis in patients on anti TNF-α therapies and the effectiveness of azole prophylaxis in this group are needed before definitive recommendations can be made.
We describe a case of fatal miliary coccidioidomycosis in a 78 year old white man taking the anti-TNF agent infliximab. The patient had vacationed briefly in an endemic area 6 months prior to presentation. He presented with a cheek lesion and rapidly progressive miliary lung infiltration and ultimately died from respiratory failure. This case highlights the importance of a travel history and the need for prompt investigation and diagnosis of cutaneous lesions in this patient population.
The patient's family has kindly provided writteninformedconsent for the case report to be published. The authors declare that they have no funding.
- Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB: Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004, 109 (14): 1718-1723. 10.1161/01.CIR.0000124720.18538.DD.View ArticlePubMedGoogle Scholar
- Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006, 174 (7): 795-802. 10.1164/rccm.200603-402OC.View ArticlePubMedGoogle Scholar
- Desai SB, Furst DE: Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006, 20 (4): 757-790. 10.1016/j.berh.2006.06.002.View ArticlePubMedGoogle Scholar
- Chang JT, Lichtenstein GR: Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2006, 3 (4): 220-228. 10.1038/ncpgasthep0447.View ArticlePubMedGoogle Scholar
- Saubolle MA, McKellar PP, Sussland D: Epidemiologic, Clinical and Diagnostic Aspects of Coccidioidomycosis. J Clin Microbiol. 2006Google Scholar
- Hector RF, Laniado-Laborin R: Coccidioidomycosis--a fungal disease of the Americas. PLoS Med. 2005, 2 (1): e2-10.1371/journal.pmed.0020002.View ArticlePubMedPubMed CentralGoogle Scholar
- DiCaudo DJ: Coccidioidomycosis: a review and update. J Am Acad Dermatol. 2006, 55 (6): 929-42; quiz 943-5. 10.1016/j.jaad.2006.04.039.View ArticlePubMedGoogle Scholar
- Blair JE, Logan JL: Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001, 33 (9): 1536-1544. 10.1086/323463.View ArticlePubMedGoogle Scholar
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama. 2006, 295 (19): 2275-2285. 10.1001/jama.295.19.2275.View ArticlePubMedGoogle Scholar
- Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004, 50 (6): 1959-1966. 10.1002/art.20454.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.